{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T01:42:45Z","timestamp":1784770965428,"version":"3.55.0"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      Antimicrobial resistance poses a major challenge in the treatment of\n                      <jats:italic>A. baumannii<\/jats:italic>\n                      worldwide, especially\n                      <jats:italic>Carbapenem-Resistant A. baumannii<\/jats:italic>\n                      (CRAB) bloodstream infections.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The objective of this study was to isolate and characterize a CRAB-targeting bacteriophage and to evaluate its therapeutic potential, alone and in combination with polymyxin B.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      From January 2020 to September 2025, adult patients with\n                      <jats:italic>A. baumannii<\/jats:italic>\n                      bloodstream infection were enrolled. Clinically relevant data were collected.\n                      <jats:italic>A. baumannii<\/jats:italic>\n                      strains were isolated from clinical samples and the phage was isolated from wastewater samples collected from hospital by double-layer agar plate method. The synergistic activity of phage\u2013polymyxin B combination therapy was assessed by checkerboard analysis and time-kill assays. BALB\/c mice were infected with a CRAB suspension via tail vein to establish the model and were subsequently treated with the phage and phage-antibiotic combination.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 50 patients suffered from bloodstream infections caused by Acinetobacter baumannii. Among them, 34 (68%) cases were classified as CRAB. Compared with CSAB, they underwent a longer duration of mechanical ventilation(13.00(6.00,28.00) vs.3.00(2.00,4.00),P =0.019), used more triple therapy(9.41% vs.0%,P=0.041), and had a higher in-hospital mortality(82.35% vs.18.75%,P &amp;lt;0.001). Synergistic antibacterial activity between the phage and colistin B was demonstrated using the checkerboard assay and time-kill curve analysis. In a murine bacteremia model, the vB_AbaP_CV1-antibiotic combination significantly reduced tissue bacterial loads, attenuated inflammatory responses, and ameliorated clinical manifestations. Notably, the combined therapy exhibited superior therapeutic efficacy compared to either monotherapy alone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>CRAB bloodstream infections are associated with high mortality and poor outcomes. vB_AbaP_CV1 can lyse the CRAB strains. Both phage monotherapy and the phage-colistin B combination exhibited therapeutic efficacy, with the combined regimen yielding the optimal outcome.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcimb.2026.1774993","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T05:43:43Z","timestamp":1775022223000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Carbapenem-resistant Acinetobacter baumannii bloodstream infections and specific phages isolation, analysis and application"],"prefix":"10.3389","volume":"16","author":[{"given":"Lu","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Critical Care Medicine, The Affiliated Hospital of Qingdao University","place":["Qingdao, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuhua","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Critical Care Medicine, The Affiliated Hospital of Qingdao University","place":["Qingdao, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyong","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Critical Care Medicine, The Affiliated Hospital of Qingdao University","place":["Qingdao, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Critical Care Medicine, The Affiliated Hospital of Qingdao University","place":["Qingdao, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajun","family":"Jing","sequence":"additional","affiliation":[{"name":"Department of Critical Care Medicine, The Affiliated Hospital of Qingdao University","place":["Qingdao, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinyan","family":"Xing","sequence":"additional","affiliation":[{"name":"Department of Critical Care Medicine, The Affiliated Hospital of Qingdao University","place":["Qingdao, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,1]]},"reference":[{"key":"B1","unstructured":"WHObacterial priority pathogens list, 2024: bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance\n          \n          \n          2024"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijregi.2023.01.002","article-title":"Epidemiology and mortality outcome of carbapenem- and colistin-resistant Klebsiella pneumoniae, Escherichia coli, Acinetobacter baumannii, and Pseudomonas aeruginosa bloodstream infections","volume":"7","author":"Balkhair","year":"2023","journal-title":"IJID Reg."},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2018.00696","article-title":"Characterization of two novel bacteriophages infecting multidrug-resistant (MDR) Acinetobacter baumannii and evaluation of their therapeutic efficacy in vivo","volume":"9","author":"Cha","year":"2018","journal-title":"Front. Microbiol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12941-020-00389-5","article-title":"Bacteriophage therapy against Pseudomonas aeruginosa biofilms: A review","volume":"19","author":"Chegini","year":"2020","journal-title":"Ann. Clin. Microbiol. Antimicrob."},{"key":"B5","doi-asserted-by":"publisher","first-page":"33892","DOI":"10.1038\/s41598-025-09530-w","article-title":"Characterization of carbapenem-resistant biofilm forming Acinetobacter baumannii isolates from clinical and surveillance samples","volume":"15","author":"Choudhary","year":"2025","journal-title":"Sci. Rep."},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1128\/MMBR.00012-19","article-title":"Pharmacologically aware phage therapy: Pharmacodynamic and pharmacokinetic obstacles to phage antibacterial action in animal and human bodies","volume":"83","author":"D\u0105browska","year":"2019","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"B7","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.ijantimicag.2009.10.024","article-title":"Multidrug-resistant Acinetobacter baumannii: Mechanisms of virulence and resistance","volume":"35","author":"Gordon","year":"2010","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00234-20","article-title":"Pathogenesis of gram-negative bacteremia","volume":"34","author":"Holmes","year":"2021","journal-title":"Clin. Microbiol. Rev."},{"key":"B9","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s40265-024-02104-6","article-title":"Treatment approaches for carbapenem-resistant Acinetobacter baumannii infections","volume":"85","author":"Iovleva","year":"2025","journal-title":"Drugs"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01063-24","article-title":"Acinetobacter baumannii treatment strategies: A review of therapeutic challenges and considerations","volume":"69","author":"Kubin","year":"2025","journal-title":"Antimicrob. Agents Chemother."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.crmicr.2024.100331","article-title":"Multidrug resistant Acinetobacter baumannii: A study on its pathogenesis and therapeutics","volume":"8","author":"Mukhopadhyay","year":"2024","journal-title":"Curr. Res. Microb. Sci."},{"key":"B12","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.ajic.2013.09.003","article-title":"Ventilator-associated pneumonia due to extensive drug-resistant Acinetobacter baumannii: Risk factors, clinical features, and outcomes","volume":"42","author":"Ozgur","year":"2014","journal-title":"Am. J. Infect. Control"},{"key":"B13","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","article-title":"European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European Society of Intensive Care Medicine)","volume":"28","author":"Paul","year":"2022","journal-title":"Clin. Microbiol. Infect."},{"key":"B14","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.jhin.2006.11.010","article-title":"Carbapenem-resistant Acinetobacter baumannii in intensive care unit patients: Risk factors for acquisition, infection and their consequences","volume":"65","author":"Playford","year":"2007","journal-title":"J. Hosp. Infect."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms9071353","article-title":"Gram-negative bacteria holding together in a biofilm: The Acinetobacter baumannii way","volume":"9","author":"Pompilio","year":"2021","journal-title":"Microorganisms"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00954-17","article-title":"Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant Acinetobacter baumannii infection","volume":"61","author":"Schooley","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"B17","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1093\/cid\/ciac268","article-title":"Infectious diseases society of america 2022 guidance on the treatment of extended-spectrum \u03b2-lactamase producing enterobacterales (esbl-e), carbapenem-resistant enterobacterales (cre), and pseudomonas aeruginosa with difficult-to-treat resistance (dtr-p. aeruginosa)","volume":"75","author":"Tamma","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"B18","unstructured":"Infectious diseases society of america 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections\n          \n          ciae403\n          \n            \n              Tamma\n              P. D.\n            \n            \n              Heil\n              E. L.\n            \n            \n              Justo\n              J. A.\n            \n            \n              Mathers\n              A. J.\n            \n            \n              Satlin\n              M. J.\n            \n            \n              Bonomo\n              R. A.\n            \n          \n          10.1016\/j.ajic.2013.09.003\n          24485378\n          Clin. Infect. Dis\n          \n          2024"},{"key":"B19","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1093\/cid\/ciy752","article-title":"Control of carbapenem-resistant Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa in healthcare facilities: A systematic review and reanalysis of quasi-experimental studies","volume":"68","author":"Tomczyk","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"B20","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1093\/cid\/ciad556","article-title":"Clinical outcomes and bacterial characteristics of carbapenem-resistant Acinetobacter baumannii among patients from different global regions","volume":"78","author":"Wang","year":"2024","journal-title":"Clin. Infect. Dis."},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2024.1395260","article-title":"Treatment of infections caused by carbapenem-resistant Acinetobacter baumannii","volume":"14","author":"Zhang","year":"2024","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"e59","DOI":"10.1016\/j.ajic.2013.01.006","article-title":"Risk factors and mortality of patients with nosocomial carbapenem-resistant Acinetobacter baumannii pneumonia","volume":"41","author":"Zheng","year":"2013","journal-title":"Am. J. Infect. Control"},{"key":"B23","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.jiph.2018.02.003","article-title":"Antibiotic consumption versus the prevalence of multidrug-resistant Acinetobacter baumannii and Clostridium difficile infections at an ICU from 2014-2015","volume":"11","author":"Zi\u00f3\u0142kowski","year":"2018","journal-title":"J. Infect. Public Health"},{"key":"B24","doi-asserted-by":"publisher","first-page":"15188","DOI":"10.1038\/s41598-023-42505-3","article-title":"Bacteriophages with depolymerase activity in the control of antibiotic resistant Klebsiella pneumoniae biofilms","volume":"13","author":"Zurabov","year":"2023","journal-title":"Sci. Rep."}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2026.1774993\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T05:43:44Z","timestamp":1775022224000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2026.1774993\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":24,"alternative-id":["10.3389\/fcimb.2026.1774993"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2026.1774993","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,1]]},"article-number":"1774993"}}